Alumis Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALMS Nasdaq 2834 www.alumis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alumis Inc.

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2026 6:10 am
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug - May 10th, 2026 3:53 am
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 5:05 pm
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Apr 6th, 2026 3:09 pm
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Apr 4th, 2026 11:07 am
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Apr 3rd, 2026 9:12 pm
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says - Mar 30th, 2026 9:25 am
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout - Mar 29th, 2026 7:02 pm
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - Mar 28th, 2026 11:30 am
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - Mar 19th, 2026 2:05 pm
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - Mar 18th, 2026 6:00 am
Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run - Mar 10th, 2026 4:12 pm
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead - Mar 9th, 2026 10:02 pm
Alumis to Present at the Leerink Partners Global Healthcare Conference - Mar 2nd, 2026 6:05 am
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference - Feb 26th, 2026 6:10 pm
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - Feb 12th, 2026 9:42 am
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Feb 7th, 2026 1:03 pm
Alumis to Participate in Upcoming February Investor Conferences - Feb 5th, 2026 6:05 am
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - Feb 3rd, 2026 8:06 am
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Jan 30th, 2026 7:48 am